PMID- 14657713
OWN - NLM
STAT- MEDLINE
DCOM- 20040105
LR  - 20190823
IS  - 0147-5185 (Print)
IS  - 0147-5185 (Linking)
VI  - 27
IP  - 12
DP  - 2003 Dec
TI  - Primary cutaneous diffuse large B-cell lymphoma: prognostic significance of 
      clinicopathological subtypes.
PG  - 1538-45
AB  - Classification and subdivision of primary cutaneous diffuse large B-cell lymphoma 
      (PCDLBCL) are a matter of ongoing debate. In this study we assessed the 
      morphologic, immunophenotypic, and clinical features of 30 cases of PCDLBCL 
      identified during a review of all primary cutaneous B-cell lymphomas in the 
      Scotland and Newcastle Lymphoma Group database. We also determined the number of 
      cases harboring t(14;18) using a polymerase chain reaction and primers to the 
      major breakpoint cluster region. The effect on prognosis of a variety of clinical 
      and pathologic factors was assessed for the group of 30 PCDLBCL and the 5-year 
      disease-specific survival (DSS) of this cohort compared with that of 195 cases of 
      stage I diffuse large B-cell lymphoma arising primarily in lymph nodes, also 
      identified from within the Scotland and Newcastle Lymphoma Group database. 
      Location on the leg was the only independent prognostic factor for determining 
      outcome in PCDLBCL (67% 5-year DSS compared with 100% for the upper body; P = 
      0.0047). The presence of multiple lesions, involvement of more than one body 
      site, and expression or not of CD10, bcl-2, bcl-6, and CD10 and bcl-6, had no 
      effect on survival. Compared with cases arising above the waist, those on the leg 
      were more often female, were of an older age, and had a significantly higher 
      incidence of bcl-2 expression (P = 0.002) as well as the aforementioned poorer 
      prognosis. They also showed more frequent co-expression of CD10 and bcl-6, 
      supporting a follicle center cell origin for some, but this difference was not 
      statistically significant. Although there was no significant difference in the 
      5-year DSS between the group of PCDLBCL and the cases of stage I nodal diffuse 
      large B-cell lymphoma (88% 5-year DSS vs. 78%; P = 0.06), the latter were 
      generally treated with more aggressive therapy. Moreover, a significant 
      difference in 5-year DSS was seen when the nodal DLBCLs were compared with 
      PCDLBCLs arising above the waist (78% vs. 100% respectively; P = 0.0135). These 
      results support the current EORTC approach of subdividing PCLBCL on the basis of 
      site to produce prognostically relevant groupings.
FAU - Goodlad, John R
AU  - Goodlad JR
AD  - Department of Pathology, Raigmore Hospital, Inverness, Scotland, United Kingdom. 
      John.Goodlad@raigmore.scot.nhs.uk
FAU - Krajewski, Andrew S
AU  - Krajewski AS
FAU - Batstone, Paul J
AU  - Batstone PJ
FAU - McKay, Pam
AU  - McKay P
FAU - White, Jo M
AU  - White JM
FAU - Benton, E Claire
AU  - Benton EC
FAU - Kavanagh, Gina M
AU  - Kavanagh GM
FAU - Lucraft, Helen H
AU  - Lucraft HH
CN  - Scotland and Newcastle Lymphoma Group
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Surg Pathol
JT  - The American journal of surgical pathology
JID - 7707904
RN  - 0 (Biomarkers, Tumor)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Age Factors
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers, Tumor/*metabolism
MH  - Female
MH  - Humans
MH  - Leg/pathology
MH  - Lymphoma, B-Cell/*mortality/*pathology/therapy
MH  - Lymphoma, Large B-Cell, Diffuse/*mortality/*pathology/therapy
MH  - Male
MH  - Middle Aged
MH  - Polymerase Chain Reaction
MH  - Prognosis
MH  - Sex Factors
MH  - Survival Analysis
MH  - Treatment Outcome
MH  - Upper Extremity/pathology
EDAT- 2003/12/06 05:00
MHDA- 2004/01/06 05:00
CRDT- 2003/12/06 05:00
PHST- 2003/12/06 05:00 [pubmed]
PHST- 2004/01/06 05:00 [medline]
PHST- 2003/12/06 05:00 [entrez]
AID - 10.1097/00000478-200312000-00006 [doi]
PST - ppublish
SO  - Am J Surg Pathol. 2003 Dec;27(12):1538-45. doi: 10.1097/00000478-200312000-00006.